Batavia Biosciences is excited to announce its new Alliance for Regenerative Medicine (ARM) membership. ARM is a premier international advocacy organization that brings regenerative medicines and advanced therapies to patients worldwide. By joining ARM, Batavia Biosciences is committed to advancing the cell and gene therapy field.
“By aligning ourselves with the Alliance for Regenerative Medicine, we are strengthening our commitment to the broader cell and gene therapy community. Our primary objective is to help innovators develop and deliver ground-breaking therapies that can change and save lives,” says Peter Abbink, PhD, Managing Director at Batavia Biosciences, Inc., located in Woburn, MA. “Our extensive expertise in bioprocessing makes us a valuable partner in accelerating the journey of these therapies from the lab to the market. We aspire to be a key collaborator in a consortium where we can substantially contribute to enhancing the quality of life for patients and caregivers.”
Batavia Biosciences has a strong track record of offering state-of-the-art development and manufacturing solutions for viral vectors and is an integral player in the cell and gene therapy field. Through its cutting-edge HIP-Vax® platform technologies and services, Batavia Biosciences facilitates the rapid development and scalable manufacturing of life-changing therapies, while significantly reducing the cost of goods. Innovative bioprocess intensification technologies pave the way for significantly improved production of viral vector products, used in gene therapy and immuno-oncology.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and modernize healthcare systems so patients benefit from durable, potentially curative treatments.
As the global voice of the sector, we represent more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.
